Sanofi to go after ‘undruggable’ targets in $700M immunology deal with Belharra
Sanofi heads out to surf Belharra in $700M biobucks immunology deal
As it deepens immunology bets, Sanofi inks small molecule pact with Belharra
Belharra CEO Jeff Jonker Talks with Endpoint News About New “Birth of a Biotech” Podcast Series
Birth of a Biotech Podcast and Belharra CEO Featured in Fierce Pharma Article
Belharra’s Very Own Mike Lazear Listed as one of the 2024 Rising Stars in Proteomics by JPR
Versant-backed Belharra: light-based chemoproteomics for all amino acids
Belharra debuts with chemoproteomics engine to tackle undruggable targets
Belharra Launches with $130M From Versant, Genentech to Advance Chemoproteomics Platform
Belharra’s wave catches Genentech in $130M launch for new drug discovery engine
Belharra Named to the NextGen Class of 2024: Top Life Sciences Startups to Watch This Year
The Small Molecule Drug Discovery Renaissance: Jeff Jonker on The Long Run
Belharra Excited to be Among C&EN’s 10 Start-ups to Watch in 2024
Scripps Spinout Belharra Unveils $130M to Catch Next Big Wave of Drug Discovery
Belharra Gets $130M from Versant, Genentech For Chemoproteomic Discovery
$2B+ Genentech deal propels Belharra to the crest of the chemoproteomics wave
Belharra debuts with $130M in funding, Genentech partnership
Vividion 2.0? Ben Cravatt and Scripps team form a new chemoproteomics biotech